Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026HaematologicaOpen Access

Final results of UK NCRI phase II trial of pembrolizumab and radiotherapy in cutaneous T cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

TITimothy IllidgeWWWilliam WilsonJPJames Paterson

Discussion

Loading...

Member takes

Overview

Randomized trial investigates pembrolizumab's efficacy with radiotherapy in advanced cutaneous T-cell lymphoma, suggesting new treatment options.

Key Points

  • This trial aimed to evaluate the efficacy of pembrolizumab with radiotherapy in patients with advanced cutaneous T-cell lymphoma.
  • Single-arm multicentre phase II trial enrolled 46 relapsed/refractory CTCL patients, median age 63.
  • Patients received pembrolizumab followed by 12Gy radiotherapy to localized lesions in 3 fractions.
  • Primary endpoint was overall response rate, with secondary endpoints including overall survival and progression-free survival.
  • Overall response rate was 24% with 57% of patients still receiving treatment after 1 year.
  • Median follow-up duration was 24.8 months, indicating sustained response efforts.
  • Patients included 41 with mycosis fungoides and 5 with Sézary syndrome, with 24% at stage IV.

Cite This Study

Illidge et al. (2026) studied this question.

synapsesocial.com/papers/6a65a306d3aea3239cd765a1https://doi.org/10.3324/haematol.2025.288878
View Full Paper
Ask AI
Bookmark
Share